Guo H - Search Results

1

A prognostic index for nasal-type early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.

Hong H, Huang H, Fang X, Wang Z, Ye S, Zhang H, Huang Y, Guo H, Chen X, Liang C, Pu X, Cao Y, Lin S, Li X, Ren Q, Liu Q, Lin T. Hong H, et al. Among authors: guo h. Am J Hematol. 2019 May;94(5):E122-E124. doi: 10.1002/ajh.25426. Epub 2019 Feb 14. Am J Hematol. 2019. PMID: 30690754 Free article. Clinical Trial. No abstract available.

2

[Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients].

Pu XX, Deng YH, Xu F, Xiao J, Guo HQ, Huang H, Tian Y, He YJ, Lin TY. Pu XX, et al. Among authors: guo hq. Zhonghua Wei Chang Wai Ke Za Zhi. 2009 Nov;12(6):594-7. Zhonghua Wei Chang Wai Ke Za Zhi. 2009. PMID: 19921572 Chinese.

3

The role of Skp2 in extranodal NK/T-cell lymphoma.

Guo HQ, Pu XX, Guo CC, Rao HL, Li HR, Lin TY. Guo HQ, et al. Chin J Cancer. 2010 May;29(5):567-71. doi: 10.5732/cjc.009.10645. Chin J Cancer. 2010. PMID: 20426910 Free article.

4

Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression.

Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tian Y, Lin TY. Pu XX, et al. Among authors: guo cc, guo hq. J Gastroenterol Hepatol. 2010 Oct;25(10):1674-80. doi: 10.1111/j.1440-1746.2010.06417.x. J Gastroenterol Hepatol. 2010. PMID: 20880178

5

Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma.

Guo HQ, Huang GL, Guo CC, Pu XX, Lin TY. Guo HQ, et al. Dis Markers. 2010;29(5):251-8. doi: 10.3233/DMA-2010-0755. Dis Markers. 2010. PMID: 21206010 Free PMC article.

6

p63 Expression is a prognostic factor in colorectal cancer.

Guo HQ, Huang GL, Liu OF, Liu YY, Yao ZH, Yao SN, Zhao Y, Liu T, Pu XX, Lin TY, Yang SJ. Guo HQ, et al. Int J Biol Markers. 2012 Oct 8;27(3):e212-8. doi: 10.5301/JBM.2012.9581. Int J Biol Markers. 2012. PMID: 23015401 Free article.

7

Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications.

Pu X, Pan Z, Huang Y, Tian Y, Guo H, Wu L, He X, Chen X, Zhang S, Lin T. Pu X, et al. Among authors: guo h. Oncol Lett. 2013 Jan;5(1):249-254. doi: 10.3892/ol.2012.963. Epub 2012 Oct 10. Oncol Lett. 2013. PMID: 23255930 Free PMC article.

8

Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma.

Guo HQ, Liu L, Wang XF, Lin TY, Yao SN, Yao ZH, Yang SJ. Guo HQ, et al. Mol Clin Oncol. 2014 Nov;2(6):1172-1176. doi: 10.3892/mco.2014.368. Epub 2014 Aug 1. Mol Clin Oncol. 2014. PMID: 25279218 Free PMC article.

9

Expression of activating transcription factor 7 is correlated with prognosis of colorectal cancer.

Guo HQ, Ye S, Huang GL, Liu L, Liu OF, Yang SJ. Guo HQ, et al. J Cancer Res Ther. 2015 Apr-Jun;11(2):319-23. doi: 10.4103/0973-1482.148688. J Cancer Res Ther. 2015. PMID: 26148593 Free article.

10

Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.

Li X, Huang H, Xu B, Guo H, Lin Y, Ye S, Yi J, Li W, Wu X, Wang W, Zhan H, Xie D, Peng J, Cao Y, Pu X, Guo C, Hong H, Wang Z, Fang X, Zhou Y, Lin S, Liu Q, Lin T. Li X, et al. Among authors: guo c, guo h. Cancer Res Treat. 2019 Jul;51(3):919-932. doi: 10.4143/crt.2018.230. Epub 2018 Oct 2. Cancer Res Treat. 2019. PMID: 30282447 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19,743 results

Search Page